Medicare To Accept C-Peptide Test Alternative For Insulin Pump Coverage
This article was originally published in The Gray Sheet
Executive Summary
CMS' modification to its insulin pump national coverage policy, while broadening access to the technology, falls short of Medtronic's full request
You may also be interested in...
Compliance Matters Should Be Exempt From Coverage Requests – Medtronic
CMS' consideration of recalls associated with Medtronic's 508 and Paradigm insulin infusion pumps is "inappropriate" in the context of deciding whether to alter national coverage criteria for insulin pump therapy, the firm contends
Compliance Matters Should Be Exempt From Coverage Requests – Medtronic
CMS' consideration of recalls associated with Medtronic's 508 and Paradigm insulin infusion pumps is "inappropriate" in the context of deciding whether to alter national coverage criteria for insulin pump therapy, the firm contends
Caregivers Weigh In On CMS Insulin Pump Coverage: C-peptide Test Must Go
CMS should eliminate its requirement that all patients seeking coverage for insulin pumps demonstrate abnormally low C-peptide levels, according to the American Association of Clinical Endocrinologists